ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment

• Published in: Clinical cancer research 2018-03, Vol.24 (6), p.1500-1510
• Main Authors: Mastoraki, Sophia, Strati, Areti, Tzanikou, Eleni, Chimonidou, Maria, Politaki, Eleni, Voutsina, Alexandra, Psyrri, Amanda, Georgoulias, Vassilis, Lianidou, Evi
• Format: Article
• Language: English
• Subjects: Biomarkers; Biopsy; Breast cancer; Cancer; Deoxyribonucleic acid; DNA; DNA methylation; Epigenetics; ErbB-2 protein; ESR1 protein; Experimental design; Fish; Metastases; Paraffin; Patients; Peripheral blood; Plasma; Real time; Tumor cells; Tumors
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-17-1181

Liquid biopsy provides real-time monitoring of tumor evolution and response to therapy through analysis of circulating tumor cells (CTCs) and plasma-circulating tumor DNA (ctDNA). epigenetic silencing potentially affects response to endocrine treatment. We evaluated methylation in CTCs and paired plasma ctDNA. We evaluated methylation in CTCs and paired plasma ctDNA as a potential biomarker for response to everolimus/exemestane treatment. A highly sensitive and specific real-time MSP assay for methylation was developed and validated in (i) 65 primary breast tumors formalin-fixed paraffin-embedded (FFPE), (ii) EpCAM CTC fractions (122 patients and 30 healthy donors; HD), (iii) plasma ctDNA (108 patients and 30HD), and (iv) in CTCs (CellSearch) and in paired plasma ctDNA for 58 patients with breast cancer. methylation status was investigated in CTCs isolated from serial peripheral blood samples of 19 patients with ER /HER2 advanced breast cancer receiving everolimus/exemestane. methylation was detected in: (i) 25/65 (38.5%) FFPEs, (ii) : 26/112 (23.3%) patients and 1/30 (3.3%) HD, and (iii) 8/108 (7.4%) patients and 1/30 (3.3%) HD. methylation was highly concordant in 58 paired DNA samples, isolated from CTCs (CellSearch) and corresponding plasma. In serial peripheral blood samples of patients treated with everolimus/exemestane, methylation was observed in 10/36 (27.8%) CTC-positive samples, and was associated with lack of response to treatment ( = 0.023, Fisher exact test). We report for the first time the detection of methylation in CTCs and a high concordance with paired plasma ctDNA. methylation in CTCs was associated with lack of response to everolimus/exemestane regimen. methylation should be further evaluated as a potential liquid biopsy-based biomarker. .